Table 3 Clinical Trials Targeting IL-13/IL-4 Signaling
Agent | Company | Mechanism | Status |
|---|---|---|---|
CAT-354 | Cambridge Antibody Technology, Medimmune/AstraZeneca | Anti-IL-13 mAb | Phase IIa |
QAX576 | Novartis | Anti-IL-13 mAb | Completed phase II |
IMA-638 (Anrukinzumab) | Wyeth | Humanized Anti-IL-13 mAb | Completed phase II |
IMA-026 | Wyeth | Anti-IL-13 mAb | Phase II |
MILR1444A (Lebrikizumab) | Genentech | Humanized Anti-IL-13 mAb | Phase II |
AIR645 | Altair Therapeutics | Anti-sense targeting mRNA for IL4Rα1 | Phase IIa |
AER001 (Pitrakinra) | Aerovance | Human IL-4 mutein inhibits IL13Rα1 or IL2Rγ) from assembly into receptor complexes w/IL4Rα | Completed phase II |
AMG317 | Amgen | Human Anti-IL-4Rα mAb | Completed phase II |